Shares of Akums Medicine and Prescribed drugs Ltd fell 1.5% on twenty fifth August after touching a day’s excessive of Rs 491.95. This occurred regardless of the corporate saying plans to arrange a producing facility in Zambia.
The agency introduced on twenty second August that it has signed an settlement with the Authorities of Zambia to determine an area manufacturing facility. The venture will concentrate on producing oral solids, liquids, injectables, and beta-lactam merchandise. Completion is focused by 2028.
Akum-Zambia Joint Enterprise
The power can be developed beneath a three way partnership. Akums will maintain a 51% majority stake and the Zambian authorities will personal the remaining 49%. Each events will put money into the venture in proportion to their shareholdings.
Future Growth Plans
As a part of the settlement, the Zambian authorities will buy medicines value $50 million over 2026 and 2027 (USD 25 million yearly) from Akums and its subsidiaries in India. The power additionally goals to assist Zambia’s nationwide well being programmes and enhance native manufacturing. It can additionally broaden exports to Southern African nations, together with Botswana, Malawi, Mozambique, Namibia, Tanzania, and Zimbabwe.
Akums Medicine Q1 Outcomes
For Q1 FY2025, Akums reported a web revenue of Rs 63.48 crore, up 5.50% from Rs 60.17 crore a yr earlier. Gross sales rose marginally by 0.48% to Rs 1024.03 crore.
At 11:31 AM, the shares of Akums Medicine have been buying and selling 1.55% decrease at Rs 472.60 on NSE.
Prepared to take a position like a professional? Unicorn Alerts app equips you with 100+ Free instruments and data you should succeed. Obtain the Unicorn Alerts app and acquire entry to day by day inventory lists and insightful market evaluation and way more!
